Can Shanting commonly known as secukinumab , officially known as secukinumab suitable for Chine

Judging from the current clinical trial data of the Chinese population, Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is very suitable for Chinese use. Keshanting (commonly known as "secukinumab", officially known as "secukinumab") has conducted phase III clinical trials in the Chinese population. The results showed that among all Chinese patients with moderate to severe plaque psoriasis who received Coshanting (commonly known as "secukinumab", officially known as "secukinumab") 300 mg (the recommended dose for the label)**:

Nearly 98% of patients achieved a PASI 75 response (i.e., 75% reduction in size and severity of psoriasis, significant improvement in skin lesions) and nearly 81% achieved a PASI 90 response (i.e., 90% reduction in psoriasis size and severity, with almost clear lesions) at week 12; Nearly ninety percent of patients achieved a PASI 90 response at week 16; Symptoms resolved within 3 weeks. From these clinical data, it can be demonstrated that Keshanting (commonly known as "secukinumab", officially known as "secukinumab") has clinically meaningful efficacy in Chinese patients with moderate to severe psoriasis.

Chapter 49 Three Tibetan Disasters and Sinking Water House, Guanyin Rescues the Fish Basket Chapter 50 Emotional Disorder, From Lust, Dizzy and Heartbeat, Meets the Devil.

To put it bluntly, this monoclonal antibody is a clone of an antibody, which is an antibody extracted from the body of a patient who has had psoriasis for 20 years, because psoriasis is difficult to produce antibodies. Even in patients who are 20 years old, the antibodies in the body can only make up for the complete killing of the virus, which can only reduce its incidence.

Sucukinumab (Keshanting) is a drug approved by the National Medical Products Administration in April 2019 for the use of adult patients with moderate to severe plaque psoriasis who are **systemic** or phototherapy indications. At the same time, secukinumab (Keshanting) is also the world's first and only fully human interleukin-17a (IL-17A) inhibitor, which inhibits its pro-inflammatory effect and alleviates psoriasis symptoms without hindering the normal work of other cytokines by specifically binding to any ** interleukin-17a.

Keshanting (commonly known as secukinumab) is currently the longest-used IL-17A inhibitor in clinical use in the world, and is the only one with 5 years of long-term safety clinical data, with a good safety profile. Most of the common respiratory tract infections are common, and most of the adverse events are mild or moderate; The risk of tuberculosis** is very low; There is no difference in the risk of developing cancer from the general population.

I need to popularize it with you, psoriasis is an immune-related chronic, **sexual, inflammatory, and systemic disease, which may be lifelong **, and arthropathic psoriasis may lead to joint deformities and even disability. At present, it is still not possible to **, and long-term medication management is required.

However, Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is currently the world's first and only fully human IL-17A inhibitor that exhibits 5 years of sustained or almost clear skin lesion clearance in stage III psoriasis**, and can maintain nearly 100% of the PASI response rate (i.e., psoriasis area and severity remission) for up to 5 years, that is, if used continuously, it can effectively control the disease.

At the same time, for the efficacy of coshanting (commonly known as "secukinumab", officially known as "secukinumab"), the subject can also refer to the clinical trial data of the Chinese population, among all Chinese patients with moderate to severe plaque psoriasis who received coshanting (commonly known as "secukinumab", officially known as "secukinumab") 300mg (the recommended dose of the instructions)**: nearly 98% of patients achieved a PASI 75 response (i.e., a 75% reduction in psoriasis area and severity) by week 12, lesions improved markedly), and nearly 81% of patients achieved a PASI 90 response (i.e., 90% reduction in the size and severity of psoriasis, with almost clear lesions); Nearly ninety percent of patients achieved a PASI 90 response at week 16; Symptoms resolved within 3 weeks. These data can demonstrate the effectiveness of coshantinab (commonly known as "secukinumab", officially known as "secukinumab") for psoriasis.

Regarding whether it will be ** after stopping the drug, Ke Shanting (commonly known as "secukinumab", officially known as "secukinumab") is indeed a study, the data statistics are that after the patient has experienced a washout period for a long time, after receiving 300mg for the last **, 21% and 10% of the patients have not ** for at least 1 year and 2 years**, but the subject you have to be clear that psoriasis is a disease that requires continuous medication to better control the condition, and if it is good, it is necessary to stop the drug without authorization** Risk, because there is another study that also showed that 75% of patients will develop ** after stopping the drug, so it is really recommended not to stop the drug without authorization.

If it is caused by stopping the drug without authorization, you can follow the doctor's instructions and continue to use Keshanting (commonly known as "secukinumab", officially known as "secukinumab").

Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is mainly used for moderate to severe plaque psoriasis ** that meets the indications of systemic **or phototherapy). Because Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is currently the world's first and only fully human interleukin-17a (IL-17A) inhibitor, and interleukin-17a (IL-17A) is the core agent directly involved in the inflammation and disease progression of psoriasis, and plays a cornerstone role in the pathogenesis. Therefore, Keshanting (commonly known as "secukinumab", officially known as "secukinumab") can be effective in ** psoriasis (commonly known as "psoriasis").

Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is a drug approved by the National Medical Products Administration in April 2019 for adult patients with moderate to severe plaque psoriasis who **meet the indications for systemic** or phototherapy. At the same time, Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is also the world's first and only fully human interleukin-17a (IL-17A) inhibitor, which inhibits its pro-inflammatory effect and alleviates psoriasis symptoms without hindering the normal work of other cytokines by specifically binding to any ** interleukin-17a. Because interleukin-17a is the core cause of psoriasis, inhibiting too much interleukin-17a can quickly relieve symptoms and eliminate skin lesions, so Keshanting (commonly known as "secukinumab", officially known as "secukinumab") is an effective drug for psoriasis.